Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. on January 6, 2021. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial performance data.
Material Changes
On January 6, 2021, the Board of Directors appointed Michael Quigley, Ph.D., as a Class III Director. Dr. Quigley serves as the Senior Vice President of Research Biology at Gilead Sciences, Inc. This appointment was made pursuant to an Investor Rights Agreement between Arcus and Gilead, which was established in connection with agreements signed on May 27, 2020.
Guidance, Outlook, and Risks
Dr. Quigley will not receive compensation for his service on the Board. The company expects to enter into its standard form of indemnification agreement with him. The filing does not contain updated financial guidance, management commentary on operations, or new risk factors beyond the context of the Gilead collaboration.
Key Facts for Investors to Verify
- Confirmation of Michael Quigley's appointment as a Class III Director effective January 6, 2021.
- Verification that the appointment stems from the Investor Rights Agreement with Gilead Sciences, Inc.
- Confirmation that the new director will serve without direct compensation.
- Review of the May 27, 2020 Option, License, Collaboration, and Common Stock Purchase Agreements with Gilead for context on the relationship.